{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:55:10Z","timestamp":1787874910837,"version":"build-2784847793"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Reducing the risk of exacerbation is a fundamental goal in managing stable chronic obstructive pulmonary disease (COPD). Guidelines recommend triple therapy (inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting \u03b2-agonists) only as a stepup from dual therapy (long-acting muscarinic antagonists and long-acting \u03b2-agonists) for patients at continued high risk of exacerbation, because of the trade-off of an increased risk of pneumonia associated with inhaled corticosteroid\u2013containing therapies. However, there is little evidence on the optimum timing of initiating triple therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To perform a benefit\u2013harm analysis to evaluate the net benefit of earlier initiation of triple therapy for the prevention of acute exacerbations in patients with COPD compared with standard timing recommended in current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a validated whole-disease microsimulation model of COPD in the Canadian general population aged \u2a7e40\u2009years to determine the benefit versus harm of earlier initiation of triple therapy over a 20-year time horizon compared with standard care. We assessed net change in quality-adjusted life-years (QALYs) from the reduction in risk of acute exacerbations and the increased risk of treatment-related pneumonia in subgroups of patients with COPD defined by exacerbation history, symptoms, and disease severity. Model parameters were determined from clinical trials and other published literature. Key parameters were varied in one-way sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In patients at high risk of acute exacerbation (54.7% female; mean age, 74.0\u2009yr; 68% Global Initiative for Chronic Obstructive Lung Disease grades I and II), earlier initiation of triple therapy was associated with a net QALY gain of 4.8 per 100 patients with COPD over 20\u2009years compared with standard care. The net QALY gain increased to 5.9 per 100 patients in the subgroup of patients with a high symptom burden (modified Medical Research Council dyspnea scale score, &amp;gt;1). Earlier initiation remained net beneficial in all subgroup and sensitivity analysis scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Modeling suggests that earlier initiation of triple therapy is likely to be net beneficial for patients at high risk of acute exacerbation, with an even greater benefit to patients with a high symptom burden. Further clinical research is needed to verify these findings in empirical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202311-990oc","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:31:35Z","timestamp":1712320295000},"page":"1139-1146","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":7,"title":["Benefit\u2013Harm Analysis of Earlier Initiation of Triple Therapy for Prevention of Acute Exacerbation in Patients with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-4529","authenticated-orcid":false,"given":"Rachael","family":"Mountain","sequence":"first","affiliation":[{"name":"Centre for Health Informatics, Computing, and Statistics, Lancaster Medical School, Lancaster University, Lancaster, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-6611","authenticated-orcid":false,"given":"Kevin I.","family":"Duan","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7406-2448","authenticated-orcid":false,"given":"Kate M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, and"},{"name":"Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2026012203162627400_bib1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(18)31891-9","article-title":"Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Dicker","year":"2018","journal-title":"Lancet"},{"key":"2026012203162627400_bib2","first-page":"210","article-title":"Canadian Thoracic Society clinical practice guideline on pharmacotherapy in patients with COPD\u20142019 update of evidence","volume":"3","author":"Bourbeau","year":"2019","journal-title":"Can J Respir Crit Care Sleep Med"},{"key":"2026012203162627400_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1378\/chest.06-1610","article-title":"Impact of COPD exacerbations on patient-centered outcomes","volume":"131","author":"Cote","year":"2007","journal-title":"Chest"},{"key":"2026012203162627400_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"2026012203162627400_bib5","volume-title":"Pocket guide to COPD diagnosis, management, and prevention","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2020"},{"key":"2026012203162627400_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012203162627400_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012203162627400_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"2026012203162627400_bib9","doi-asserted-by":"crossref","first-page":"105950","DOI":"10.1016\/j.intimp.2019.105950","article-title":"Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials","volume":"77","author":"Yang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026012203162627400_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.chest.2017.07.002","article-title":"Long-term use of inhaled corticosteroids in COPD and the risk of fracture","volume":"153","author":"Gonzalez","year":"2018","journal-title":"Chest"},{"key":"2026012203162627400_bib11","doi-asserted-by":"crossref","first-page":"e0162903","DOI":"10.1371\/journal.pone.0162903","article-title":"Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study","volume":"11","author":"Price","year":"2016","journal-title":"PLoS One"},{"key":"2026012203162627400_bib12","first-page":"CD002991","article-title":"Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease","volume":"3","author":"Yang","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012203162627400_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0272989X08323299","article-title":"A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives","volume":"29","author":"Felli","year":"2009","journal-title":"Med Decis Making"},{"key":"2026012203162627400_bib14","doi-asserted-by":"crossref","first-page":"k4388","DOI":"10.1136\/bmj.k4388","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"key":"2026012203162627400_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/crj.13026","article-title":"Triple versus dual inhaler therapy in moderate-to-severe COPD: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Zayed","year":"2019","journal-title":"Clin Respir J"},{"key":"2026012203162627400_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12931-019-1213-9","article-title":"Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review","volume":"20","author":"Langham","year":"2019","journal-title":"Respir Res"},{"key":"2026012203162627400_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0272989X18824098","article-title":"Development and validation of the evaluation platform in COPD (EPIC): a population-based outcomes model of COPD for Canada","volume":"39","author":"Sadatsafavi","year":"2019","journal-title":"Med Decis Making"},{"key":"2026012203162627400_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40258-020-00616-2","article-title":"Cost effectiveness of case detection strategies for the early detection of COPD","volume":"19","author":"Johnson","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"2026012203162627400_bib19","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1513\/AnnalsATS.202304-301OC","article-title":"A cost-effectiveness analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease","volume":"20","author":"Ahmadian","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203162627400_bib20","doi-asserted-by":"crossref","first-page":"E1048","DOI":"10.9778\/cmajo.20230023","article-title":"Budget impact analysis of adopting primary care-based case detection of chronic obstructive pulmonary disease in the Canadian general population","volume":"11","author":"Mountain","year":"2023","journal-title":"CMAJ Open"},{"key":"2026012203162627400_bib21","author":"Canadian Institute of Health Information (CIHI)","year":"2016"},{"key":"2026012203162627400_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/15412555.2012.665520","article-title":"Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD","volume":"11","author":"Bourbeau","year":"2014","journal-title":"COPD"},{"key":"2026012203162627400_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/COPD.S13826","article-title":"Association between lung function and exacerbation frequency in patients with COPD","volume":"5","author":"Hoogendoorn","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012203162627400_bib24","author":"University of British Columbia, Respiratory Evaluation Sciences Program (RESP)"},{"key":"2026012203162627400_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012203162627400_bib26","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012203162627400_bib27","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012203162627400_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","volume":"15","author":"D\u2019Urzo","year":"2014","journal-title":"Respir Res"},{"key":"2026012203162627400_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2026012203162627400_bib30","volume-title":"Economic model report for inhaled triple therapy: chronic obstructive pulmonary disease in over 16s: diagnosis and management: Report No. 9781473134683","author":"National Institute for Health and Care Excellence (NICE)","year":"2019"},{"key":"2026012203162627400_bib31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"2026012203162627400_bib32","volume-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"Canada\u2019s Drug and Health Technology Agency (CADTH)","year":"2017","edition":"4th ed."},{"key":"2026012203162627400_bib33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","article-title":"Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease","volume":"23","author":"Spencer","year":"2005","journal-title":"PharmacoEconomics"},{"key":"2026012203162627400_bib34","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/archinte.1996.00440130115012","article-title":"Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia","volume":"156","author":"Coley","year":"1996","journal-title":"Arch Intern Med"},{"key":"2026012203162627400_bib35","doi-asserted-by":"crossref","first-page":"e0186777","DOI":"10.1371\/journal.pone.0186777","article-title":"Adherence to inhaled therapies of COPD patients from seven Latin American countries: the LASSYC study","volume":"12","author":"Montes de Oca","year":"2017","journal-title":"PLoS One"},{"key":"2026012203162627400_bib36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2147\/COPD.S290805","article-title":"Are COPD prescription patterns aligned with guidelines? Evidence from a Canadian population-based study","volume":"16","author":"Bahremand","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012203162627400_bib37","author":"Statistics Canada","year":"2023"},{"key":"2026012203162627400_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203162627400_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12931-020-01354-8","article-title":"Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study","volume":"21","author":"Mackay","year":"2020","journal-title":"Respir Res"},{"key":"2026012203162627400_bib40","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1378\/chest.121.5.1434","article-title":"Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD","volume":"121","author":"Nishimura","year":"2002","journal-title":"Chest"},{"key":"2026012203162627400_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","article-title":"Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review","volume":"23","author":"Hurst","year":"2022","journal-title":"Respir Res"},{"key":"2026012203162627400_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12890-022-01892-5","article-title":"Understanding barriers to and strategies for medication adherence in COPD: a qualitative study","volume":"22","author":"O\u2019Toole","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012203162627400_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12931-018-0882-0","article-title":"What have we learned from observational studies and clinical trials of mild to moderate COPD?","volume":"19","author":"Barrecheguren","year":"2018","journal-title":"Respir Res"},{"key":"2026012203162627400_bib44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203162627400_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR special task force report","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"}],"updated-by":[{"DOI":"10.1513\/annalsats.22i3erratum1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000}}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/8\/1139\/66008419\/annalsats_21_8_1139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/8\/1139\/66008419\/annalsats_21_8_1139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:17:35Z","timestamp":1769069855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/8\/1139\/8380702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202311-990oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"2023-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}